Sign in
Not yet recruitingPhase 2

Teprotumumab N01 or steroids after eye surgery for thyroid optic nerve damage

Compares teprotumumab N01 with steroids after surgery in dysthyroid optic neuropathy.

Key facts

Who runs it
Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy
Status
Not yet recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
Aug 2026
Expected to end
Apr 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Teprotumumab N01
  • Intravenous Methylprednisolone (IVMP)
Record updated
19 May 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Able and willing to provide written informed consent
  • Age 18 to 65 years
  • Clinical diagnosis of thyroid eye disease (TED) with dysthyroid optic neuropathy (DON). Diagnosis of DON must meet both of the following criteria:; Visual dysfunction not explained by other causes, such as decreased best-corrected visual acuity, visual field defect, abnormal color vision, or relative afferent pupillary defect; Imaging evidence of orbital apex crowding, optic nerve compression, or optic nerve stretching
  • The study eye meets the criteria for urgent orbital decompression, defined as either of the following:; Poor response after rescue intravenous methylprednisolone for the current dysthyroid optic neuropathy episode, with a cumulative methylprednisolone-equivalent dose of no more than 3.0 g, defined as no improvement or continued deterioration of visual function within 1 to 2 weeks; Contraindication to glucocorticoids or investigator judgment that direct urgent mechanical decompression is required
  • Thyroid function is normal or mildly abnormal before enrollment, with free triiodothyronine (FT3) and free thyroxine (FT4) within 50% above or below the normal reference range when possible
  • Alanine aminotransferase (ALT) no more than 1.5 times the upper limit of normal, aspartate aminotransferase (AST) no more than 3 times the upper limit of normal, and serum creatinine no more than 1.5 times the upper limit of normal
  • For participants with diabetes mellitus, hemoglobin A1c (HbA1c) less than 9.0% and stable antidiabetic treatment within 60 days before enrollment
  • For women of childbearing potential, a pregnancy test must be negative before enrollment
  • Participants of reproductive potential agree to use effective contraception during the study and for 90 days after the last dose of study treatment
  • Able and willing to comply with study treatment and follow-up procedures

Who cannot take part

  • Orbital decompression surgery within 6 months before screening
  • Systemic glucocorticoid treatment for non-thyroid eye disease within 3 months before screening with cumulative methylprednisolone-equivalent dose of 1.0 g or greater
  • Tocilizumab or other systemic immunosuppressive treatment within 3 months before screening, or rituximab within 6 months before screening
  • Orbital radiotherapy within 3 months before screening
  • Previous treatment with teprotumumab
  • Other ocular diseases that may significantly affect visual function assessment, including glaucomatous optic neuropathy, macular disease, severe cataract, or non-thyroid eye disease optic neuropathy
  • History of definite inner ear disease or clinically significant hearing impairment
  • Severe cardiovascular disease
  • Severe hepatic or renal disease
  • Active infection or clinically significant infectious disease, including active hepatitis, HIV infection, syphilis, or active tuberculosis
  • Active gastrointestinal ulcer
  • History of malignancy judged by the investigator to be unsuitable for enrollment
  • Known allergy to monoclonal antibodies, methylprednisolone, or any study drug excipient
  • Uncontrolled diabetes mellitus or any other condition that, in the investigator's judgment, makes the participant unsuitable for the study
  • Clinically significant abnormal blood test results, including white blood cell count less than 4.0 × 10\^9/L, platelet count less than 80 × 10\^9/L, hemoglobin less than 110 g/L in males or less than 100 g/L in females
  • Bilateral dysthyroid optic neuropathy requiring urgent bilateral orbital decompression at baseline
  • Cumulative preoperative methylprednisolone-equivalent dose greater than 3.0 g for the current dysthyroid optic neuropathy episode
  • Irreversible optic nerve damage in the study eye with very low potential for visual recovery, as judged by the investigator
  • Pregnancy or breastfeeding

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate the efficacy and safety of sequential Teprotumumab N01 compared with intravenous methylprednisolone (IVMP) after urgent orbital decompression in patients with dysthyroid optic neuropathy (DON).

The 2 groups in the trial

  • Postoperative Sequential Teprotumumab N01Treatment being tested

    Participants in this arm will undergo urgent orbital decompression and then receive postoperative sequential Teprotumumab N01.

    Treatment: Teprotumumab N01

  • Postoperative Sequential Intravenous MethylprednisoloneExisting treatment, for comparison

    Participants in this arm will undergo urgent orbital decompression and then receive postoperative sequential intravenous methylprednisolone.

    Treatment: Intravenous Methylprednisolone (IVMP)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single-Center, Prospective, Randomized, Open-Label, Parallel-Group Study Comparing Sequential Teprotumumab N01 With Intravenous Methylprednisolone After Urgent Orbital Decompression in Patients With Dysthyroid Optic Neuropathy
Plain-language title
Teprotumumab N01 or steroids after eye surgery for thyroid optic nerve damageGenerated from the registry record. The registry title is the official one.
Criteria questions
Built from NCT07594912, who can take part
Record updated
19 May 2026